Biotech Values

[dewophile]

Yes management bungled this. My guess is they saw the favorable response in the very first pt enrolled who had prologned SD w DLBCL who relapsed post transplant where average survival is only around 3 months then a PR at that same low dose and they thought they had a home run on their hands, which obviously was not the case when data from later cohorts came in